Here's a story that didn't get the headlines it might have. MedCity reports that "IBM is dumping" IBM WATSON, its much-touted, formerly much-hyped program, and "for salvage value," here. See also a story at Quartz, "What Went Wrong?" here. Similarly, NYT last summer here. On the sale, some additional quotes and links here.
AI has to be approached carefully; see a current JAMA article discussing problems with the historical roll-out in the past decade of computer assisted detection in mammography - here.
On the Other Hand
On the other hand - in focused domains, there are really interesting things going on.
See an article on an AI-based improvement in measuring PDL1 and tumor infiltrating lymphocytes, here. And see a MedCity article on digital pathology companies collaborating with major health centers toward focused goals, here.